Enzyme Structure May Lead to Control of DNA Methylation Process
|
By LabMedica International staff writers Posted on 20 Feb 2018 |

Image: The DNMT3A-DNA complex. The structure reveals that DNMT3A molecules attack two substrate sites adjacent to each other on the same DNA molecule. DNMT3L (green) is a regulatory protein of DNMT3A (Photo courtesy of the Song Laboratory, University of California, Riverside).
The recently established molecular structure of the enzyme DNA methyltransferase 3A bound to its DNA substrate is expected to eventually lead to the ability to control DNA methylation content and, by extension, gene expression and cell differentiation.
DNA methylation catalyzed by the de novo DNA methyltransferases 3A (DNMT3A) and 3B (DNMT3B) at cytosine residues is essential for genome regulation and development. Disruption of this process has been implicated in various diseases, notably cancer. However, the mechanisms underlying DNMT3 substrate recognition and enzymatic specificity have remained elusive.
To better understand this mechanism, investigators at the University of California, Riverside (USA) solved the 2.65-ångström crystal structure of the DNMT3A–DNMT3L–DNA complex. They described in the February 7, 2018, online edition of the journal Nature the state in which two DNMT3A monomers simultaneously attacked two cytosine–phosphate–guanine (CpG) dinucleotides, with the target sites separated by 14 base pairs within the same DNA duplex.
The DNMT3A–DNA interaction involved a target recognition domain, a catalytic loop, and DNMT3A homodimeric interface. A specific arginine residue in the target recognition domain was shown to make crucial contacts with CpG, ensuring DNMT3A's enzymatic preference towards CpG sites in cells.
"The structure reveals that DNMT3A molecules attack two substrate sites adjacent to each other on the same DNA molecule," said senior author Dr. Jikui Song, associate professor of biochemistry at the University of California, Riverside. "This now offers us a much clearer view on how de novo DNA methylation takes place. Our work presents the first structural view of de novo DNA methylation and presents a model for how some DNMT3A mutations contribute to cancers, such as acute myeloid leukemia. This study should provide important insights into the function of DNMT3B as well."
"Before our study, why mammalian DNA methylation mostly occurs at the CpG sites was not understood, and our understanding of de novo DNA methylation was purely based on computational modeling, which cannot reliably explain how DNMT3A works," said Dr. Song. "Just how DNMT3A succeeded in binding to its substrate was not understood either. Our structure for DNMT3A-DNA complex addresses all these concerns, offering a far better understanding of how specific DNA methylation patterns are generated."
Related Links:
University of California, Riverside
DNA methylation catalyzed by the de novo DNA methyltransferases 3A (DNMT3A) and 3B (DNMT3B) at cytosine residues is essential for genome regulation and development. Disruption of this process has been implicated in various diseases, notably cancer. However, the mechanisms underlying DNMT3 substrate recognition and enzymatic specificity have remained elusive.
To better understand this mechanism, investigators at the University of California, Riverside (USA) solved the 2.65-ångström crystal structure of the DNMT3A–DNMT3L–DNA complex. They described in the February 7, 2018, online edition of the journal Nature the state in which two DNMT3A monomers simultaneously attacked two cytosine–phosphate–guanine (CpG) dinucleotides, with the target sites separated by 14 base pairs within the same DNA duplex.
The DNMT3A–DNA interaction involved a target recognition domain, a catalytic loop, and DNMT3A homodimeric interface. A specific arginine residue in the target recognition domain was shown to make crucial contacts with CpG, ensuring DNMT3A's enzymatic preference towards CpG sites in cells.
"The structure reveals that DNMT3A molecules attack two substrate sites adjacent to each other on the same DNA molecule," said senior author Dr. Jikui Song, associate professor of biochemistry at the University of California, Riverside. "This now offers us a much clearer view on how de novo DNA methylation takes place. Our work presents the first structural view of de novo DNA methylation and presents a model for how some DNMT3A mutations contribute to cancers, such as acute myeloid leukemia. This study should provide important insights into the function of DNMT3B as well."
"Before our study, why mammalian DNA methylation mostly occurs at the CpG sites was not understood, and our understanding of de novo DNA methylation was purely based on computational modeling, which cannot reliably explain how DNMT3A works," said Dr. Song. "Just how DNMT3A succeeded in binding to its substrate was not understood either. Our structure for DNMT3A-DNA complex addresses all these concerns, offering a far better understanding of how specific DNA methylation patterns are generated."
Related Links:
University of California, Riverside
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples
Channels
Clinical Chemistry
view channel
Chemical Imaging Probe Could Track and Treat Prostate Cancer
Prostate cancer remains a leading cause of illness and death among men, with many patients eventually developing resistance to standard hormone-blocking therapies. These drugs often lose effectiveness... Read more
Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
Creatinine has long been the standard for measuring kidney filtration, while cystatin C — a protein produced by all human cells — has been recommended as a complementary marker because it is influenced... Read moreMolecular Diagnostics
view channel
Simple Urine Test to Revolutionize Bladder Cancer Diagnosis and Treatment
Bladder cancer is one of the most common and deadly urological cancers and is marked by a high rate of recurrence. Diagnosis and follow-up still rely heavily on invasive cystoscopy or urine cytology, which... Read more
Blood Test to Enable Earlier and Simpler Detection of Liver Fibrosis
Persistent liver damage caused by alcohol misuse or viral infections can trigger liver fibrosis, a condition in which healthy tissue is gradually replaced by collagen fibers. Even after successful treatment... Read moreHematology
view channel
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read moreImmunology
view channel
New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection
Since HIV was identified in 1983, more than 91 million people have contracted the virus, and over 44 million have died from related causes. Today, nearly 40 million individuals worldwide live with HIV-1,... Read more
Gene Signature Test Predicts Response to Key Breast Cancer Treatment
DK4/6 inhibitors paired with hormone therapy have become a cornerstone treatment for advanced HR+/HER2– breast cancer, slowing tumor growth by blocking key proteins that drive cell division.... Read more
Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
Ductal carcinoma in situ (DCIS) accounts for about a quarter of all breast cancer cases and generally carries a good prognosis. This non-invasive form of the disease may or may not become life-threatening.... Read moreMicrobiology
view channel
Rapid Diagnostic Test Matches Gold Standard for Sepsis Detection
Sepsis kills 11 million people worldwide every year and generates massive healthcare costs. In the USA and Europe alone, sepsis accounts for USD 100 billion in annual hospitalization expenses.... Read moreRapid POC Tuberculosis Test Provides Results Within 15 Minutes
Tuberculosis remains one of the world’s deadliest infectious diseases, and reducing new cases depends on identifying individuals with latent infection before it progresses. Current diagnostic tools often... Read more
Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples
Bloodstream infections in sepsis progress quickly and demand rapid, precise diagnosis. Current blood-culture methods often take one to five days to identify the pathogen, leaving clinicians to treat blindly... Read morePathology
view channel
Tunable Cell-Sorting Device Holds Potential for Multiple Biomedical Applications
Isolating rare cancer cells from blood is essential for diagnosing metastasis and guiding treatment decisions, but remains technically challenging. Many existing techniques struggle to balance accuracy,... Read moreAI Tool Outperforms Doctors in Spotting Blood Cell Abnormalities
Diagnosing blood disorders depends on recognizing subtle abnormalities in cell size, shape, and structure, yet this process is slow, subjective, and requires years of expert training. Even specialists... Read moreTechnology
view channel
Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Identifying which genetic variants actually cause disease remains one of the biggest challenges in genomic medicine. Each person carries tens of thousands of DNA changes, yet only a few meaningfully alter... Read more
AI Saliva Sensor Enables Early Detection of Head and Neck Cancer
Early detection of head and neck cancer remains difficult because the disease produces few or no symptoms in its earliest stages, and lesions often lie deep within the head or neck, where biopsy or endoscopy... Read moreIndustry
view channel
Abbott Acquires Cancer-Screening Company Exact Sciences
Abbott (Abbott Park, IL, USA) has entered into a definitive agreement to acquire Exact Sciences (Madison, WI, USA), enabling it to enter and lead in fast-growing cancer diagnostics segments.... Read more








